Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.

Autor: D'Hondt C; Centre for Reproductive Medicine (CRG), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium., Vanhoeij M; Breast Cancer Clinic, Oncologisch Centrum, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Van Moer E; Centre for Reproductive Medicine (CRG), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium., Segers I; Centre for Reproductive Medicine (CRG), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium., Fontaine C; Breast Cancer Clinic, Oncologisch Centrum, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium., Tournaye H; Centre for Reproductive Medicine (CRG), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium., De Vos M; Centre for Reproductive Medicine (CRG), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium. mdevos@uzbrussel.be.; Department of Obstetrics, Gynecology, Perinatology and Reproductology, Institute of Professional Education, Sechenov University, Moscow, Russia. mdevos@uzbrussel.be.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2020 Nov; Vol. 184 (2), pp. 433-444. Date of Electronic Publication: 2020 Aug 13.
DOI: 10.1007/s10549-020-05858-1
Abstrakt: Purpose: To investigate whether fertility preservation (FP) in adult women diagnosed with breast cancer (BC) may impact the time interval between diagnosis and start of chemotherapy in an adjuvant or neo-adjuvant setting.
Methods: Retrospective cohort study of breast cancer patients diagnosed between January 2012 and December 2017 undergoing FP at a tertiary-care academic fertility centre before neo-adjuvant (NAC) or adjuvant chemotherapy (AC), and matched control breast cancer patients who had no FP. FP interventions included oocyte vitrification following ovarian stimulation or after in-vitro maturation (IVM) of immature oocytes, and/or ovarian tissue cryopreservation. Controls from the patient database of the affiliated Breast Cancer Clinic were matched for tumour characteristics and type of treatment. Time intervals between cancer diagnosis and the start of chemotherapy were analysed.
Results: Fifty-nine BC patients underwent FP: 29 received NAC and 30 received AC. The average interval between diagnosis and chemotherapy in BC patients with NAC was 28.5 days (27.3 (range: 14.0-44.0) days in cases and 29.6 (range: 14.0-62.0) days in controls (NS)); this interval was 58.9 days in BC patients with AC (57.2 (range: 36.0-106.0) days in cases and 60.7 (range: 31.0-105.0) days in controls (NS)).
Conclusion: Fertility preservation does not delay the start of chemotherapy in breast cancer patients.
Databáze: MEDLINE
Externí odkaz: